Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Neuro Panel: Wingspan Stent’s Probable Benefits No Longer Outweigh Risks

This article was originally published in The Gray Sheet

Executive Summary

Recent post-market study data leads FDA’s Neurological Devices panel to conclude that the intracranial stent system, which gained humanitarian device exemption approval in 2005, no longer shows probable benefits outweighing the risks.

You may also be interested in...

FDA Narrows Indication For Stryker’s Wingspan Intracranial Stent

Agency restricts use of the device to a select patient population with severe intracranial stenosis and recurrent stroke after reviewing studies indicating the device could actually lead to increased rates of stroke and death.

Regulatory News In Brief

Group urges FDA to pull Stryker’s Wingspan stent from the market, among other regulatory updates.

Stryker Buys Target Neurovascular Biz From Boston Scientific For $1.5 Billion

Stryker will enter the neurovascular market and become segment leader through the $1.5 billion purchase of Target Therapeutics from Boston Scientific, the firms announced Oct. 28.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts